Log In
BCIQ
Print this Print this
 

Pabrinex

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionHigh potency formulation of vitamins B and C
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Endocrine (unspecified)
Indication DetailsTreat symptoms of malabsorption especially in patients with acute alcohol problems
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$394.4M

$394.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2014

$394.4M

$394.4M

0

Get a free BioCentury trial today